PRKCH

PRKCH (PKCη/PKC-L) is a phorbol ester- and diacylglycerol-responsive serine/threonine kinase that functions in gene expression control, cancer cell motility, and vascular and metabolic signaling (PMID:1986216, PMID:41115563). Recombinant enzyme binds phorbol esters comparably to classical PKC isoforms but acts on conventional PKC substrates (histone, myelin basic protein, protamine) with distinct behavior, marking it as functionally divergent from group A PKC enzymes (PMID:1590767). Unlike classical PKCs, PKCη localizes constitutively and specifically to the nucleus and is resistant to phorbol ester-induced down-regulation (PMID:1545811). In cancer contexts, PRKCH suppresses the p53/p21 axis to promote growth and invasion and counteracts miR-24-3p-mediated tumor suppression (PMID:27351203), and it operates downstream of a ROCK1–ERK2–CREB1 transcriptional axis—with CREB1 binding the PRKCH promoter—to drive colorectal cancer cell migration and bioenergetic reprogramming of glycolysis and mitochondrial respiration (PMID:41115563). Its transcript is regulated post-transcriptionally through 3'-UTR targeting, linking PRKCH to mTOR-dependent osteogenic signaling (PMID:35271849). A rare K65R missense mutation enhances PKCη localization and signaling at the Golgi apparatus, connecting aberrant Golgi-localized activity to Alzheimer's disease risk [PMID:bio_10.1101_2025.05.13.25327562].

1. 1991 Medium

   Established that the PRKCH gene product is a functional phorbol ester-binding kinase, defining it as a PKC family enzyme.

   Evidence cDNA expression in COS cells with phorbol ester binding and kinase activity assays

   PMID:1986216

   Open questions at the time

   • No physiological substrate identified
   • Activation mechanism beyond phorbol esters undefined
2. 1992 High

   Reconstitution of recombinant enzyme showed PKCη binds phorbol esters like classical isoforms yet handles conventional PKC substrates differently, distinguishing it from group A PKCs and implying a unique substrate specificity.

   Evidence Baculovirus/insect-cell recombinant protein, phorbol ester binding and in vitro kinase assays with multiple substrates

   PMID:1590767

   Open questions at the time

   • Bona fide endogenous substrates not identified
   • Whether incomplete activation vs. true specificity unresolved
3. 1992 High

   Defined PKCη's unusual constitutive nuclear localization and resistance to phorbol ester down-regulation, setting it apart from classical PKCs and pointing to a role in nuclear/gene-expression functions.

   Evidence Immunofluorescence and subcellular fractionation across multiple human cell lines

   PMID:1545811

   Open questions at the time

   • Nuclear targeting determinants unknown
   • Nuclear substrates not identified
4. 2007 Low

   Linked PRKCH expression to vascular disease, showing enrichment in endothelial cells and foamy macrophages of progressing atherosclerotic lesions.

   Evidence Immunohistochemistry of human atherosclerotic tissue

   PMID:17206144

   Open questions at the time

   • Single descriptive localization method without functional manipulation
   • Causal role in lesion progression untested
5. 2016 Medium

   Placed PRKCH upstream of tumor-suppressive signaling by showing it suppresses the p53/p21 pathway to drive carcinoma growth and invasion.

   Evidence Overexpression/knockdown, Western blot, mRNA quantification, and miR-24-3p rescue assays in adenoid cystic carcinoma cells

   PMID:27351203

   Open questions at the time

   • Direct vs. indirect mechanism of p53/p21 repression unclear
   • Kinase activity requirement not tested
6. 2020 Low

   Associated PRKCH with RAF/MEK/ERK survival signaling in leukemia cells, where its down-regulation accompanied reduced ERK activity and increased apoptosis.

   Evidence Drug (HQH) treatment with Western blot, RT-qPCR, viability/apoptosis assays, and MEK4 perturbation in Ph+ leukemia cells

   PMID:32337697

   Open questions at the time

   • Pathway placement inferred from expression changes, not direct PRKCH manipulation
   • Causal contribution of PRKCH to apoptosis unproven
7. 2022 Medium

   Showed PRKCH is post-transcriptionally controlled via its 3'-UTR and acts upstream of mTOR, linking it to osteogenic gene regulation.

   Evidence Luciferase 3'-UTR reporter, Western blot, and proteomics in osteoblast subclones

   PMID:35271849

   Open questions at the time

   • Mechanism by which PRKCH activates mTOR undefined
   • Direct kinase-substrate relationship not shown
8. 2025 Medium

   Defined an upstream transcriptional circuit (ROCK1–ERK2–CREB1) driving PRKCH and connected PRKCH to cancer cell motility and metabolic reprogramming.

   Evidence ROCK1/PRKCH perturbation, PRKCH-promoter luciferase reporter, ERK2/CREB1 inhibition, Seahorse assays, and in vivo colonization in CRC cells

   PMID:41115563

   Open questions at the time

   • PRKCH kinase substrates mediating metabolic effects unknown
   • Direct CREB1 promoter occupancy in vivo not shown
9. 2025 Medium

   Connected a PRKCH coding variant to disease by showing the K65R mutation enhances Golgi localization and signaling of PKCη, implicating aberrant Golgi-localized activity in Alzheimer's disease risk.

   Evidence Family-based GWAS, whole genome sequencing, and localization/signaling assays for the K65R mutant (preprint)

   PMID:bio_10.1101_2025.05.13.25327562

   Open questions at the time

   • Not yet peer-reviewed
   • Mechanism by which K65R redirects localization to Golgi unresolved
   • Downstream AD-relevant substrates undefined

• The physiological substrates and the molecular basis of PKCη's distinct substrate specificity and compartment-specific (nuclear vs. Golgi) signaling remain unresolved.
• No direct endogenous kinase substrate identified
• Structural basis of substrate selectivity unknown
• Determinants of nuclear vs. Golgi targeting uncharacterized